Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0000921895-25-000684
Filing Date
2025-03-04
Accepted
2025-03-04 09:27:19
Documents
4

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 24808
2 DIRECTORS AND OFFICERS ex1tosc13d09076068_03042025.htm EX-1 3758
3 TRANSACTIONS IN SECURITIES ex2tosc13d09076068_03042025.htm EX-2 50175
4 GROUP AGREEMENT, DATED MARCH 4, 2025 ex991to13d09076068_030425.htm EX-99.1 25412
  Complete submission text file 0000921895-25-000684.txt   105625
Mailing Address 2727 KIRBY DRIVE UNIT 29L HOUSTON TX 77098
Business Address
Radoff Bradley Louis (Filed by) CIK: 0001380585 (see all company filings)

Type: SCHEDULE 13D

Mailing Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110
Business Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110 857-204-8109
Atea Pharmaceuticals, Inc. (Subject) CIK: 0001593899 (see all company filings)

EIN.: 460574869 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-91836 | Film No.: 25701815
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)